Clinical Trials at Duke Comprehensive Cancer Center

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact giclintrials@duke.edu or contact Shawna Savage, RN or Liz Anderson, RN at (919) 684-6342.

Trial Phase New Anti-Cancer Drugs (Phase I)
00004928 I An Open Label Phase I Dose Finding Study of TRC105 in Patients with Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable
00004929 I A Phase I/Biomarker Study of Bevacizumab in Combination with CNTO 95 in Patients with Refractory Solid Tumors
00005540 I Open-Label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects with Advanced Malignancies
00012090 I A Phase IB Study of Sorafenib for Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma and Child's B Cirrhosis
00009948 I/II A Phase I/II, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination with A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients with Advanced Solid Tumors
00000682 I A Phase I, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of EZN-2968, a Locked Nucleic Acid Antisense Oligonucleotide Against Hypoxia-Inducible Factor-1a (anti-HIF-1a LNA AS-ODN), Administered as a Weekly 2-Hour Intravenous Inf
00001082 I A Phase I Study of Bevacizumab, Everolimus and Panitumumab for Patients with Advanced Solid Tumors
00001110 I An Open Label Study to Determine the Oral MTD of the Kinase Inhibitor CEP-11981 in Patients with Advanced Cancer
00008797 I Phase I Study of ABT-510 in Combination with Bevacizumab in Advanced Solid Tumors
00014343 I Phase I, Open Label, Dose-Escalation, Multidose Study of MDX-1307, a Mannose Receptor-Targeted hCG-B Vaccine, in Patients with Incurable Colorectal, Pancreatic or Bladder Cancer.
00009767 I Phase I Study of Every Other Week Anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Monoclonal Antibody IMC-1121B in Patients with Advanced Solid Tumors Who have Not Responded to Standard Therapy
00001799 I/II A Phase I/II Study of Active Immunotherapy with CEA(6D) VRP Vaccine (AVX701) in Patients with Advanced or Metastatic Malignancies Expressing CEA
Duke Comprehensive Cancer Center Accolades